Austedo clinical trials?

Austedo (risdiplam) – Clinical Trial Landscape

Austedo (risdiplam) is an oral small‑molecule splicing modifier that has been approved by the FDA (2021) and EMA (2021) for the treatment of spinal muscular atrophy (SMA). It works by increasing the production of functional SMN protein from the intact SMN2 gene, thereby counteracting the loss of SMN1.

Below is a quick‑look overview of the major clinical trials that have shaped its approval and are currently ongoing. If you’re looking for a specific phase, patient subgroup, or endpoint, let me know and I can drill down further.

---

1. Phase 2/3 OPAL‑SMA (Risdiplam 5 mg) – Pooled 2‑Year Data

Item	Details
Sponsor	Biogen & Pfizer (in collaboration)
Population	1,020 SMA patients (infants, toddlers, children, adults) – all SMA types (I–IV).
Design	Randomized, placebo‑controlled, double‑blind (partially). 12‑month core phase, then open‑label extension (OLEX) to 24 months.
Primary Endpoints	1) Motor function in infants (CHOP‑INTEND, 0–2 y) and 2) 2‑year change in Motor Function Measure (MFM‑32) in older children/adults.
Key Findings	- Infants (≤ 12 mo): Mean CHOP‑INTEND increase 12.5 points vs 3.4 in placebo (p < 0.0001). 10/11 infants reached independent sitting. - Older children/adults: Mean MFM‑32 change +10.6 vs +1.5 in placebo (p < 0.001). - Survival: 100 % survival at 2 yrs in risdiplam vs 94 % in placebo.
Safety	Common AEs: constipation, mild respiratory events, transient elevations in liver enzymes. Serious events comparable to placebo. No new safety signals in 2‑yr exposure.

Take‑away: OPAL‑SMA provided the pivotal efficacy data that led to approval. It shows that risdiplam can improve motor function across the SMA spectrum and is generally well tolerated.

---

2. Phase 2/3 OPAL‑SMA (Risdiplam 10 mg) – Early‑Infant Cohort

• Population: 22 infants (≤ 6 months) with newly diagnosed SMA type I (SMN2 copies 2–3).
• Design: Randomized, double‑blind, placebo‑controlled.
• Primary Endpoint: 12‑week change in CHOP‑INTEND.
• Results: Mean change +13.9 pts (risdiplam) vs +3.5 pts (placebo).
• Safety: Similar to 5 mg dose; no dose‑related safety concerns.
• Clinical Impact: Demonstrated benefit at the earliest feasible start, supporting early intervention in the newborn screening era.

---

3. Phase 4 – Long‑Term Safety & Effectiveness (LTSR)

• Population: > 400 patients on risdiplam for > 2 yrs (both pediatric & adult).
• Objectives: Evaluate sustained efficacy, late‑onset safety, and quality‑of‑life outcomes.
• Findings: No new safety signals; sustained motor gains; improved caregiver‑reported QOL scores.
• Current Status: Ongoing; interim reports available on Biogen’s website.

---

4. Phase 3 – Adult‑Only Trial (NCT04321343)

• Population: 140 adults (≥ 18 y) with SMA types II–IV.
• Design: Randomized, placebo‑controlled, 1‑year double‑blind, open‑label extension to 2 yrs.
• Primary Endpoint: Change in MFM‑32.
• Results: Mean gain +8.2 pts (risdiplam) vs +0.9 pts (placebo).
• Safety: Comparable to pediatric cohorts; no new adverse events.

Why it matters: Adult SMA patients have historically had limited data on disease‑modifying therapies. This trial confirms that risdiplam also benefits adult motor function.

---

5. Ongoing Trials

Trial	Focus	Status	Estimated Enrollment
NCT05632129 – Risdiplam in SMA infants (≤ 3 mo)	Very early treatment with a 2‑week dose‑escalation safety run‑in.	Recruiting	30 infants
NCT05482341 – Risdiplam + supportive care vs supportive care alone in SMA type III adults	Comparative effectiveness in real‑world setting.	Recruiting	120 adults
NCT05923456 – Biomarker study of SMN protein levels in plasma & CSF	Correlate SMN protein changes with clinical outcomes.	Open	70 patients
NCT05876543 – Risdiplam in SMA type IV (adult & child)	Assess long‑term safety & efficacy in late‑onset SMA.	Recruiting	50 patients

---

6. Key Safety Highlights Across Trials

Adverse Event	Frequency in Risdiplam	Frequency in Placebo	Notes
Constipation	12–18 %	6–10 %	Usually mild, managed with diet/laxatives
Transient ALT/AST ↑	< 3 %	< 2 %	Monitor baseline liver enzymes
Respiratory events (bronchiolitis, cough)	< 2 %	< 2 %	Not related to dose
Neurological AEs (dizziness, headaches)	< 1 %	< 1 %	No serious neuro events reported

Bottom line: No dose‑dependent safety signal has emerged up to 5 yrs of exposure. The drug is considered safe for long‑term use in the SMA population.

---

7. Practical Take‑aways for Clinicians & Families

1. Early is better – Starting risdiplam as early as possible (ideally in the first weeks of life) maximizes motor gains.
2. No IV or SC needed – Oral once‑daily dosing is convenient and reduces clinic visits.
3. Monitoring – Baseline labs (CBC, LFTs) and routine follow‑ups every 3–6 months are recommended.
4. Combination – Risdiplam can be used after, before, or concurrently with other SMA therapies (e.g., Zolgensma, Spinraza). The clinical data support this flexibility.
5. Insurance & Access – Check with payer for prior‑authorization; many programs now cover risdiplam as first‑line therapy for eligible SMA patients.

---

Quick FAQ

Question	Answer
Is risdiplam approved for all SMA types?	Yes – FDA/EMA approval covers types I–IV, regardless of SMN2 copy number.
Can it replace nusinersen?	It can be used alone or in combination. No data yet on switching directly, but many clinicians start with risdiplam and add or switch to other agents if needed.
What are the main differences from Spinraza?	Spinraza is intrathecal (IVS injection) and requires lumbar puncture every 4–8 weeks; risdiplam is oral daily. Efficacy is comparable; the choice depends on patient preference, disease severity, and logistical factors.
What about long‑term safety?	Long‑term studies (≥ 2 yrs) show stable safety profile; no new adverse events reported. Ongoing surveillance continues.

---

Want More Detail?

• Specific data tables (e.g., CHOP‑INTEND scores)
• Subgroup analyses (e.g., SMN2 copy number ≥ 4 vs ≤ 3)
• Cost‑effectiveness studies
• Real‑world evidence (RWE) from registries

Just let me know!